Close button
Enquiry IconContact Us
Logo

Interstitial lung disease (ILD) is another term for pulmonary fibrosis, which means “scarring” and “inflammation” of the interstitium (the tissue that surrounds the lung’s air sacs, blood vessels and airways). This scarring makes the lung tissue stiff, which can make breathing difficult. ILD may be limited to the lung, or it can be related to a condition that may affect other parts of the body, such as rheumatoid arthritis or sarcoidosis. Most people with interstitial lung disease have symptoms that makes breathing difficult, such as:

  • Shortness of breath
  • Coughing
  • Decreased exercise tolerance
  • Fatigue
  • Weight loss

For instance, according to a report published 2017, in European Respiratory Journal, 1170 interstitial lung disease cases were reported. The overall prevalence was 97.9 and incidence: 19.4/year in Paris and France. The most prevalent diagnoses were sarcoidosis (42.6%), connective tissue diseases associated ILDs (CTDs-ILDs) (16%), idiopathic pulmonary fibrosis (IPF) (11.6%), and occupational ILDs (5.0%).

Global Interstitial Lung Disease Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector, which has been majorly impacted by the pandemic. Cancer patients in general and those suffering from lung cancer in particular are a vulnerable group because of their various intrinsic characteristics and care needs. Lung cancer patients require frequent radiologic study follow-ups, which had been affected due to COVID-19 pandemic. COVID-19 related incidental radiologic findings can appear in routinely scheduled radiology tests, which may be difficult to interpret. Moreover, cancer treatment induced pneumonitis may have similar radiologic features similar to those in acute SARS-CoV-2 pneumonia and lead to a wrong diagnosis. The different health care needs, the requirement for continuous health care access and follow-ups, and the clinical trials in which this patient population might be enrolled are all being affected by the current COVID-19 health crisis. Due to COVID-19 pandemic health care providers and institutions faced difficult situations and challenging ethical scenarios.

The global interstitial lung disease market is estimated to be valued at US$ 1,578.9 Mn in 2021 and is expected to exhibit a CAGR of 6.5% over the forecast period (2021-2028).

Figure 1: Global Interstitial Lung Disease Market Share (%) Analysis, By Disease Type, 2021

Interstitial Lung Disease  | Coherent Market Insights

Increasing number of drug approvals from regulatory bodies is a major factor driving the market growth over the forecast period.

Market players are focusing on gaining drug approvals from regulatory bodies, which is expected to drive the growth of global interstitial lung disease market during the forecast period. For instance, in April 2021, United Therapeutics Corporation, a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved Tyvaso (treprostinil) Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease to improve exercise ability.  

Adoption of inorganic strategies by the market players is expected to drive the market growth during the forecast period.

Increasing number of partnerships by key players are expected to boost the growth of global interstitial lung disease market during the forecast period. For instance, in September 2020, Boehringer Ingelheim (Canada) Ltd., a pharmaceutical company, announced that they had entered into partnership with the University Hospital Foundation (UHF), this partnership will focus on improving patient outcomes in the area of progressive fibrosing interstitial lung disease (PF-ILD).

CMI table icon

Interstitial Lung Disease Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021 : US$ 1,578.9 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 6.5% 2028 Value Projection: US$ 2,453.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Disease Type: Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis
  • By Drug Type: Corticosteroids, Anti-fibrotic Medication, Pirfenidone, Nintedanib
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 
Companies covered:

MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd, Inc., and Cipla.

Growth Drivers:
  • Increasing number of drug approvals from regulatory bodies
  • Adoption of inorganic growth strategies by key players
Restraints & Challenges:
  • Lack of awareness related to interstitial lung disease

Global Interstitial Lung Disease Market – Restraints

Lack of awareness related to interstitial lung disease is expected to hinder the growth of the global interstitial lung disease market during the forecast period.

For instance, in August 2021, an educational webinar was held to drive awareness of interstitial lung disease (ILD), nine organizations collaborated to present the first-ever Interstitial Lung Disease Day (ILD) on, September 15. ILD is a term which refers to more than 200 types of lung diseases, which are characterized by inflammation and scarring in the lungs. The inflammation and scarring injures the lungs, making it difficult to breathe. Nine organizations include Pulmonary Fibrosis Foundation, Arthritis Foundation, Foundation for Sarcoidosis Research, The Myositis Association, PF Warriors LLC, Scleroderma Foundation, Scleroderma Research Foundation, Sjögren’s Foundation, Inc., and WESCOE Foundation.

Global Interstitial Lung Disease Market – Regional Analysis

On the basis of region, the global interstitial lung disease market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global interstitial lung disease market, owing to increasing number of drug approvals by regulatory bodies.

For instance, in March, 2021, F. Hoffmann-La Roche Ltd, a biotech company, announced that the U.S. Food and Drug Administration (FDA) approved Actemra/RoActemra (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the US FDA for the treatment of the disease.

Figure 2: Global Interstitial Lung Disease Market Value (US$ Mn), By Region, 2020

Interstitial Lung Disease  | Coherent Market Insights

Global Interstitial Lung Disease Market – Competitive Landscape

Major players operating in the global interstitial lung disease market include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd, Inc., and Cipla.

Interstitial lung disease (ILD) is a term used for group of diseases that cause scarring (fibrosis) of the lungs. This scarring causes stiffness in the lungs, which makes difficult to breathe and supply oxygen to the bloodstream. Interstitial lung disease can be caused due to long-term exposure to hazardous materials such as asbestos. Some types of autoimmune diseases, such as rheumatoid arthritis, also can cause interstitial lung disease. The symptoms of interstitial lung disease include:

  • Shortness of breath at rest
  • Dry cough

The diseases which are grouped under interstitial lung disease are interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis. Interstitial lung disease (ILD) can be treated with medications such as corticosteroids, anti-fibrotic medication, Pirfenidone, and nintedanib.  

Market Dynamics

Increasing number of drug approvals from regulatory bodies is expected to drive the growth of global interstitial lung disease market during the forecast period. For instance, in October 2014, the U.S. Food and Drug Administration (FDA) approved pirfenidone (Esbriet) and nintedanib (Ofev) for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease that makes breathing difficult and causes irreversible lung damage.

Increasing number of drug launches is expected to drive the growth of global interstitial lung disease market. For instance, in October 2020, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the launch of NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.

Key features of the study:

  • This report provides an in-depth analysis of global interstitial lung disease market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global interstitial lung disease market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd., and Cipla
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global interstitial lung disease market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the interstitial lung disease market.

Detailed Segmentation:

  • Global Interstitial Lung Disease Market, By Disease Type:
    • Interstitial Pneumonia
    • Idiopathic Pulmonary Fibrosis
    • Nonspecific Interstitial Pneumonitis
    • Hypersensitivity Pneumonitis
    • Cryptogenic Organizing Pneumonia (COP)
    • Sarcoidosis
    • Acute Interstitial Pneumonitis
  • Global Interstitial Lung Disease Market, By Drug Type:
    • Corticosteroids
    • Anti-fibrotic Medication
    • Pirfenidone
    • Nintedanib
  • Global Interstitial Lung Disease Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Interstitial Lung Disease Market, By Region:
    • North America
      • By Disease Type:
        • Interstitial Pneumonia
        • Idiopathic Pulmonary Fibrosis
        • Nonspecific Interstitial Pneumonitis
        • Hypersensitivity Pneumonitis
        • Cryptogenic Organizing Pneumonia (COP)
        • Sarcoidosis
        • Acute Interstitial Pneumonitis
      • By Drug Type:
        • Corticosteroids
        • Anti-fibrotic Medication
        • Pirfenidone
        • Nintedanib
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Disease Type:
        • Interstitial Pneumonia
        • Idiopathic Pulmonary Fibrosis
        • Nonspecific Interstitial Pneumonitis
        • Hypersensitivity Pneumonitis
        • Cryptogenic Organizing Pneumonia (COP)
        • Sarcoidosis
        • Acute Interstitial Pneumonitis
      • By Drug Type:
        • Corticosteroids
        • Anti-fibrotic Medication
        • Pirfenidone
        • Nintedanib
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Disease Type:
        • Interstitial Pneumonia
        • Idiopathic Pulmonary Fibrosis
        • Nonspecific Interstitial Pneumonitis
        • Hypersensitivity Pneumonitis
        • Cryptogenic Organizing Pneumonia (COP)
        • Sarcoidosis
        • Acute Interstitial Pneumonitis
      • By Drug Type:
        • Corticosteroids
        • Anti-fibrotic Medication
        • Pirfenidone
        • Nintedanib
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Disease Type:
        • Interstitial Pneumonia
        • Idiopathic Pulmonary Fibrosis
        • Nonspecific Interstitial Pneumonitis
        • Hypersensitivity Pneumonitis
        • Cryptogenic Organizing Pneumonia (COP)
        • Sarcoidosis
        • Acute Interstitial Pneumonitis
      • By Drug Type:
        • Corticosteroids
        • Anti-fibrotic Medication
        • Pirfenidone
        • Nintedanib
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Disease Type:
        • Interstitial Pneumonia
        • Idiopathic Pulmonary Fibrosis
        • Nonspecific Interstitial Pneumonitis
        • Hypersensitivity Pneumonitis
        • Cryptogenic Organizing Pneumonia (COP)
        • Sarcoidosis
        • Acute Interstitial Pneumonitis
      • By Drug Type:
        • Corticosteroids
        • Anti-fibrotic Medication
        • Pirfenidone
        • Nintedanib
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Disease Type:
        • Interstitial Pneumonia
        • Idiopathic Pulmonary Fibrosis
        • Nonspecific Interstitial Pneumonitis
        • Hypersensitivity Pneumonitis
        • Cryptogenic Organizing Pneumonia (COP)
        • Sarcoidosis
        • Acute Interstitial Pneumonitis
      • By Drug Type:
        • Corticosteroids
        • Anti-fibrotic Medication
        • Pirfenidone
        • Nintedanib
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • MSD (Merck) *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Liminal Biosciences
    • Glenmark Pharma
    • B. Chemicals & Pharmaceuticals
    • Boehringer Ingelhim International GmbH
    • Hoffmann-La Roche Ltd
    • Cipla

“*” marked represents similar segmentation in other categories in the respective section.

FAQ

Frequently Asked Questions

The global interstitial lung disease market is expected to exhibit a CAGR of 6.5% during the forecast period (2021-2028).

The market is estimated to be valued at US$ 1,578.9 Mn in 2021.

MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd, Inc., and Cipla. are some of the prominent players operating in the market over the forecast period.

The market is expected to be valued at US$ 2,453.5 Mn in 2028.

Idiopathic pulmonary fibrosis is the most prevalent disease type in market.

North America is the prominent region in the market.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.